Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Elena Vega

FORGOTTEN HISTORY: Repatha landed about 36 below heart groups cost effectiveness benchmark for patients without prior heart attack or stroke - The Untold Story

A health economic analysis of Amgen's cholesterol drug Repatha found it cost-effective for high-risk adults who have never had a heart attack or stroke, coming in about 36% below a benchmark used by the American College of Cardiology and American Heart Association, according to results Amgen announced Nov. 9 at the AHA's Scientific Sessions.

Amgen described the analysis as independent and said it was led by the Duke Clinical Research Institute in collaboration with the TIMI Study Group at Mass General Brigham and Harvard. It used individual patient data from the VESALIUS-CV trial, which Amgen sponsored.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.